Methanobactins (Mbns) are small copper-binding peptidic natural products first identified in methanotrophic bacteria (Fig. 1), microorganisms that utilize methane gas a carbon source.1,2 Operons resembling the putative Mbn biosynthesis operon have recently been identified in a range of proteobacterial species via genome mining.3 I hypothesize that these operons encode the biosynthetic machinery needed to produce Mbn-like peptidic natural products, and that differing peptidic backbones and post-translational modifications will confer on these products a range of copper affinities and specificities. This expanded set of Mbns will provide drug candidates for diseases related to copper overabundance.
|Effective start/end date||7/1/14 → 6/30/16|
- American Heart Association Midwest Affiliate (14PRE20460104)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.